Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Ends Advair Co-Promotion With Mistubishi Tanabe

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline will end a co-promotion deal with Mitsubishi Tanabe for Advair (fluticasone/salmeterol) by the end of July. Starting in August, GSK will be the sole marketer of the drug in Japan. The co-promotion started last April when GSK signed up Mitsubishi to promote Advair as the top treatment for chronic obstructive pulmonary disease in Japan. One year later, GSK said it had achieved the goal demonstrated by raised product awareness among medical facilities. Advair Japanese domestic sales reached ¥37.6 billion last year. The drug faces increasing competition in the dry powder inhaler market from Symbicort (budesonide/formoterol), which is being co-promoted by AstraZeneca and Astellas. Launched in January, Symbicort sales reached ¥1.5 billion at the end of March. (Click here for more - Japanese language) "GSK To Solely Market Adoair From August" - CB News (7/2/2010)

You may also be interested in...

WHO Prequalifies Celltrion’s Rituximab

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

Medac Will Market Fresenius Kabi’s Adalimumab In Germany

Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.

Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses

Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts